Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Phase 1 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Phase 2 Completed

298 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

119 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07113964 2025-08-11

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Phase 2 Not yet recruiting

79 enrolled

Breast

Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05498155 2025-06-10

OlympiaN

Phase 2 Active not recruiting

50 enrolled

Breast

Breast Neoplasms

NCT07005583 2025-06-05

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

46 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

ROSY-O

Selumetinib and Olaparib in Solid Tumors

Study of INCB123667 in Subjects With Advanced Solid Tumors

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

PLANET

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

RADIOLA

I-SPY

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

KEYLYNK-009

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

MK-5890-003

OlympiA

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

OlympiAD

PETREMAC

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

MEDIOLA

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Olaparib In Metastatic Breast Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

SOLARA

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

ELEMENT

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

RadioPARP

PHOEBE

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NeoADAPT

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

PHOENIX

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Study to Evaluate CCS1477 in Advanced Tumours

OlympiaN

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer